In pediatric sarcoma databases, the rates of alterations of the FGFR1, FGFR2, FGFR3, and FGFR4 genes were 1.3%, 0.2%, 0.2%, and 2.4%, respectively, while in neuroblastoma tumor samples, the rates of alterations were 0.2% for each [Figure 4]. This evidence concerns the gene FGFR3 and neuroblastoma.